Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Neoadjuvant and Adjuvant Control by Precision Medicine in Rectal Cancer (SYNCOPE)
2020-003697-52Phase 4Active
- Sponsor
- Helsinki University Hospital
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of capecitabine and oxaliplatin in rectal adenocarcinoma and rectal cancer, sponsored by Helsinki University Hospital. Primary endpoints: Feasibility of systemic precision medicine approach and Postoperative ctDNA as MRD biomarker. Started Jul 2020; status: active.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on 2020-003697-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003697-52.